## **Tamorah Lewis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8204399/publications.pdf

Version: 2024-02-01



#	Article	lF	CITATIONS
1	Ventilatory Strategies in Infants with Established Severe Bronchopulmonary Dysplasia: A Multicenter Point Prevalence Study. Journal of Pediatrics, 2022, 242, 248-252.e1.	0.9	10
2	Challenges and opportunities for improving access to approved neonatal drugs and devices. Journal of Perinatology, 2022, 42, 825-828.	0.9	8
3	Corticosteroid response predicts bronchopulmonary dysplasia status at 36 weeks in preterm infants treated with dexamethasone: A pilot study. Pediatric Pulmonology, 2022, 57, 1760-1769.	1.0	2
4	Comparative Transcriptional Analysis of Patient Responders Versus Non-Responders to Glucocorticoid Treatment for Bronchopulmonary Dysplasia. Journal of the Endocrine Society, 2021, 5, A80-A80.	0.1	0
5	Inter-rater reliability of the neonatal adverse event severity scale using real-world Neonatal clinical trial data. Journal of Perinatology, 2021, 41, 2813-2819.	0.9	4
6	Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity. Survey of Ophthalmology, 2021, 66, 877-891.	1.7	18
7	Grappling With Racial Health Inequity in Pediatric Cardiology. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008099.	0.9	1
8	Health Equity Column: Framing the Importance of Health Equity and Antiracism in the NICU. Neonatology Today, 2021, , 43-47.	0.0	0
9	Increasing Resident Racial and Ethnic Diversity through Targeted Recruitment Efforts. Journal of Pediatrics, 2020, 216, 4-6.	0.9	15
10	Pharmacology of Common Analgesic and Sedative Drugs Used in the Neonatal Intensive Care Unit. Clinics in Perinatology, 2019, 46, 673-692.	0.8	21
11	Pharmacometabolomics of Respiratory Phenotypic Response to Dexamethasone in Preterm Infants at Risk for Bronchopulmonary Dysplasia. Clinical and Translational Science, 2019, 12, 591-599.	1.5	13
12	ECI biocommentary. Pediatric Research, 2019, 85, 586-586.	1.1	0
13	Improving Recognition and Reporting of Adverse Drug Reactions in the NICU: A Quality Improvement Project. Pediatric Quality & Safety, 2019, 4, e203.	0.4	3
14	Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia. Pediatric Research, 2019, 85, 625-633.	1.1	13
15	Adequate Pain Management and Sedation in the Neonate: a Fine Balance. Current Treatment Options in Pediatrics, 2018, 4, 108-118.	0.2	1
16	Precision therapeutics in the NICU: why are we missing the mark?. Journal of Perinatology, 2018, 38, 444-446.	0.9	2
17	Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier?. Pharmacogenomics, 2018, 19, 1231-1233.	0.6	5
18	Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing. Pediatric Research, 2018, 84, 325-327.	1.1	6

TAMORAH LEWIS

#	Article	IF	CITATIONS
19	Ursodeoxycholic acid versus phenobarbital for cholestasis in the Neonatal Intensive Care Unit. BMC Pediatrics, 2018, 18, 197.	0.7	18
20	Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clinical Pharmacology and Therapeutics, 2015, 98, 309-320.	2.3	23
21	The development of a high-performance liquid chromatography–tandem mass spectrometric method for simultaneous quantification of morphine, morphine-3-î²-glucuronide, morphine-6-î²-glucuronide, hydromorphone, and normorphine in serum. Clinical Biochemistry, 2015, 48, 1283-1290.	0.8	16
22	Pharmacoepidemiology of opiate use in the neonatal ICU: Increasing cumulative doses and iatrogenic opiate withdrawal. Journal of Opioid Management, 2015, 11, 305-312.	0.2	13
23	Pharmacometabolomics Profiling of Preterm Infants Validates Patterns of Metabolism Associated With Response to Dexamethasone Treatment for Bronchopulmonary Dysplasia. Frontiers in Pediatrics, 0, 10, .	0.9	3